No Seed Oil-Colon Cancer Link; Avoiding Prostate Biopsy; Top Cancer Advances

Seed oils (sunflower, sesame, etc.) are not driving the surge in colon cancer cases among younger people. (Science Feedback)

Only 4% of men with an elevated PSA but a normal MRI developed aggressive prostate cancer 3 years later, offering a biopsy-sparing approach. (JAMA Oncology)

Ten biotech companies expected to be at the forefront of therapy development in 2025. (Labiotech)

Affimed announced positive results of a single-arm study of 50 patients with heavily pretreated EGFR-mutated and wild-type advanced non-small cell lung cancer treated with atezolizumab (Tecentriq) and the bispecific immune-cell engager AFM24.

Primary radiotherapy achieved a 91% local control rate in oligometastatic/oligoprogressive thyroid cancer at 3 years. (Journal of the National Comprehensive Cancer Network)

A diet low in omega-6 and enriched with omega-3 fatty acids and fish oil for prostate cancer patients on active surveillance was associated with a reduction in a biomarker of disease progression. (UCLA Health, Journal of Clinical Oncology)

Adding the PD-1 inhibitor dostarlimab (Jemperli) to platinum-based chemotherapy and niraparib (Zejula) maintenance therapy significantly improved progression-free survival in untreated advanced ovarian cancer, GSK announced.

The American Cancer Society reviews some of the influential studies from the past year in cancer prevention, detection, treatment, and survival.

Meanwhile, cancer experts look into their crystal ball to predict major advances in cancer for 2025. (Mass General Brigham)

The FDA granted accelerated approval to encorafenib (Braftovi) plus cetuximab (Erbitux) and FOLFOX6 chemotherapy for metastatic BRAF V600E–mutant colorectal cancer.

Responding to the growing problem of cardiovascular side effects of cancer treatment, the European Society of Cardiology announced the inaugural ESC Cardio-Oncology 2025 meeting, to be held June 20-21 in Florence, Italy, the first of what is expected to be an annual meeting for cardio-oncology specialists.

A blood test involving artificial intelligence-supported laser analysis exhibited high accuracy for detecting stage 1a breast cancer and its molecular subtypes, which could enable more personalized treatment at the earliest stages. (University of Edinburgh, Journal of Biophotonics)

Charles Bankhead is senior editor for oncology and also covers urology, dermatology, and ophthalmology. He joined MedPage Today in 2007. Follow

Pulling back the curtain on psychiatric hospital joint ventures

You’re reading the web version of Health Care Inc., STAT’s weekly newsletter following the flow of money in medicine. Sign up to get it in

July 8, 2024

Many doctors are in the dark about how FDA approves devices and drugs, survey finds

In her final presentation for health policy class at the University of Chicago, first-year medical student Robin Ji informed her classmates that the Food and

January 16, 2024

Hamilton Medical’s urgent ventilator notice deemed Class I recall by FDA

Dive Brief: Hamilton Medical’s recall of ventilators for a software problem was designated Class I by the U.S. Food and Drug Administration, the agency wrote

August 31, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.